pipeline
Consano Bio is developing the first Allogeneic Multi-Protein Therapeutic, named C-1101. C-1101 delivers supraphysiological concentrations of plasma and platelet proteins to promote local cellular repair and recovery. It is developed from controlled starting materials from healthy donors and a proprietary manufacturing process.
The Untapped Potential of Platelet Therapy
Patients today have access to many significant blood-derived FDA-approved therapeutics that originated from use in medical practice. Platelet-rich plasma was first utilized in medical practice for treating orthopedic conditions in the 1980s. However, platelet-derived therapy remains an untapped modality for FDA-approved therapeutics. The field is now ripe for the next step given the significant increase in scientific studies conducted in this area and the publication of data on the use of platelet therapies over the past two decades.
C-1101 Development
C-1101 has been designed to provide supraphysiologic levels of cytokines, matrix proteins, and growth factors derived from plasma and platelets to the site of injury in the body to accelerate physiological healing.
C-1101 is intended to be delivered via an epidural injection for the treatment of chronic Lumbosacral Radiculopathy (LSR). C-1101 has been evaluated preclinically in pharmacology and safety studies. The manufacturing process has been developed and scaled to support clinical studies in the United States.
The Manufacturing Process
Novel & Proprietary Manufacturing Process Designed Specifically for C-1101
Collection of Platelets in Plasma from Large Number Healthy Donors
Controlled quality starting material
Scalable & Proprietary AMPT Drug Substance Manufacturing Process
Protein solution with consistent quantities of plasma and platelet proteins, including growth factors & cytokines required for MoA
Leverages standard biologics unit operations in novel manner
Standard Drug Product Filling Process
Ready-to-use single-dose vials for injection to site of injury
Lead Indication:
Chronic Lumbosacral Radiculopathy (LSR)
LSR is a painful condition that occurs when the nerve roots in the lumbosacral region are compressed or irritated, resulting in radiating pain and numbness. The etiology of disease includes both mechanical injury (bulging or herniated disc) and a consequential inflammatory response.
C-1101 aims to modify this disease course of chronic LSR by localizing targeted proteins that enable local healing and recovery. We anticipate submitting an IND in the second quarter of 2025 and promptly initiating a Phase 1 study in patients.